Mittal SO, et al. – The intent of this analsis was to examine the safety and efficacy of incobotulinumtoxinA (IncoA) injection for the treatment of tremor in Parkinson's disease (PD). The results displayed that the injection of IncoA via a customized approach caused an improvement in the PD tremor on a clinical scale and patient perception, with a low occurrence of notable hand weakness.

Methods

• The design of this research was a double-blind, placebo-controlled, crossover trial.
• 30 patients received 7 to 12 (mean, 9) IncoA injections into hand and forearm muscles using a customized approach.
• It was conducted from June 1, 2012, through June 30, 2015, and enrollees were followed for 24 weeks.
• Treatment efficacy was assessed through the tremor subsets of the Unified Parkinson's Disease Rating Scale and the Patient Global Impression of Change 4 and 8 weeks after each of the 2 sets of treatments.
• An ergometer evaluated the hand strength.

Results

• Notable improvement was reported in clinical rating scores of rest tremor and tremor severity 4 and 8 weeks after the IncoA injection and of action/postural tremor at 8 weeks.
• A prominent improvement was observed in patient perception of improvement at 4 and 8 weeks in the IncoA group.
• No statistically significant variation was found in grip strength at 4 weeks, between the 2 groups.